Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TMIGD2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TMIGD2 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View TMIGD2 Products |
| Gene Delivery | TMIGD2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View TMIGD2 Products |
| Benchmark Ab | Anti-TMIGD2 (Sequence of Benchmark) Recombinant positive control. |
View TMIGD2 Products |
| Validator | TMIGD2 siRNA Set For knockdown verification. |
View TMIGD2 Products |
| Related Target A | HHLA2 Primary ligand for TMIGD2 (B7-H7). |
View HHLA2 Products |
| Related Target B | KIR3DL3 Alternative inhibitory receptor for HHLA2. |
View KIR3DL3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Receptor-Ligand Binding Kinetics | HEK293 Expressed (Native Glycosylation) ECD-Fc with high purity for SPR/BLI. |
| Cell-Based Signaling Validation | Lentivirus Premade Particles for rapid stable cell line construction. |
| Lack of Controls | Clinical Benchmark Antibodies included for assay calibration. |
| False Positives | Validated siRNA included for specificity checks and background reduction. |
Live TMIGD2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for novel immune checkpoints beyond PD-1/PD-L1 is intensifying, with major players shifting focus to the HHLA2-TMIGD2 axis. TMIGD2 (CD28H) acts as a co-stimulatory receptor on T cells and NK cells. As first-generation therapies reach the clinic, the next wave of R&D is targeting the intricate balance between TMIGD2 agonism and KIR3DL3 antagonism to maximize anti-tumor immunity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Early Stage Biotechs | Solid Tumors | Binding Assays (Need high-purity ECD-Fc) |
| Bispecific Antibody | Preclinical Innovators | Refractory Cancers | Heterodimer Validation (Need Cross-reactive Abs) |
| Recombinant Protein | Academic/Biotech | Immunotherapy | Selectivity Assay (Need HHLA2/KIR3DL3 Proteins) |